Advertisement
Advertisement
CLLS
Cellectis S.A. - ADR
3.56
USDSponsored
+0.06
+1.77%
Feb 06, 16:00 UTC -5
Closed
After-Market
3.48
-0.08
-2.30%
CLLS Earnings Reports
Positive Surprise Ratio
CLLS beat 14 of 21 last estimates.
67%
Next Report
Date of Next Report
Mar 11, 2026
Estimate for Q4 25 (Revenue/ EPS)
$7.70M
/-$0.32
Implied change from Q3 25 (Revenue/ EPS)
-79.29%
/-3300.00%
Implied change from Q4 24 (Revenue/ EPS)
-49.24%
/-500.00%
Cellectis S.A. - ADR earnings per share and revenue
On Nov 07, 2025, CLLS reported earnings of 0.01 USD per share (EPS) for Q3 25, beating the estimate of -0.28 USD, resulting in a 103.50% surprise. Revenue reached 37.16 million, compared to an expected 7.11 million, with a 422.92% difference. The market reacted with a +11.29% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.32 USD, with revenue projected to reach 7.70 million USD, implying an decrease of -3300.00% EPS, and decrease of -79.29% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Cellectis S.A. - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Cellectis S.A. - ADR reported EPS of $0.01, beating estimates by 103.5%, and revenue of $37.16M, 422.92% above expectations.
How did the market react to Cellectis S.A. - ADR's Q3 2025 earnings?
The stock price moved up 11.29%, changed from $3.19 before the earnings release to $3.55 the day after.
When is Cellectis S.A. - ADR expected to report next?
The next earning report is scheduled for Mar 11, 2026.
What are the forecasts for Cellectis S.A. - ADR's next earnings report?
Based on 6
analysts, Cellectis S.A. - ADR is expected to report EPS of -$0.32 and revenue of $7.70M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement